Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems

Córdova-Gallardo, Jacqueline; Keaveny, Andrew P.; Qi, Xingshun; Méndez-Sánchez, Nahúm

doi:10.1097/meg.0000000000002335

Cited by 7 publications

(4 citation statements)

References 105 publications

(199 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Uric acid metabolism-related inflammation is involved in the pathogenesis of metabolic syndrome components, such as atherosclerosis and nonalcoholic steatohepatitis [24]. The incidence of metabolic dysfunction-associated liver disease is increasing in cases of ACLF [25,26]. Drug-induced liver injury presenting as ACLF is an important entity that is…”

Section: Discussionmentioning

confidence: 99%

A Case of Recent Liver Injury Induced by Benzbromarone

Ishii

Hoshino

Honda

et al. 2022

Reports

View full text Add to dashboard Cite

A 39-year-old male had a stomachache for 10 days before abnormal liver function tests were detected by a local doctor. Then, he was referred to us and admitted to our hospital for examination and treatment of elevated transaminases. He had taken benzbromarone to treat his hyperuricemia for seven months, and we diagnosed him with benzbromarone-induced liver injury. After the termination of benzbromarone, he finally recovered from his illness. There are several reports about benzbromarone-induced liver injury. In conclusion, as periodic liver function tests seem not to be completely performed, clinicians should regularly monitor liver function tests in patients taking benzbromarone.

show abstract

Section: Discussionmentioning

confidence: 99%

A Case of Recent Liver Injury Induced by Benzbromarone

Ishii

Hoshino

Honda

et al. 2022

Reports

View full text Add to dashboard Cite

show abstract

“…Several mechanisms linking adiposity and MAFLD to carcinogenic development include alterations in insulin metabolism, the bioavailability of insulin-like growth factor 1 (IGF-1), adipokine pathophysiology (such as adiponectin, leptin, and resistin), and increased propensity for systemic inflammation. This creates an environment conducive to the emergence of neoplasms, particularly colorectal cancer [41,[55][56][57][58][59].…”

Section: Imbalance In the Liver Metabolic Profilementioning

confidence: 99%

Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

De Cól,

de Lima,

Pompeu

et al. 2024

IJMS

Self Cite

View full text Add to dashboard Cite

Metabolic-associated fatty liver disease (MAFLD) includes several metabolic dysfunctions caused by dysregulation in the brain–gut–liver axis and, consequently, increases cardiovascular risks and fatty liver dysfunction. In MAFLD, type 2 diabetes mellitus, obesity, and metabolic syndrome are frequently present; these conditions are related to liver lipogenesis and systemic inflammation. This study aimed to review the connection between the brain–gut–liver axis and MAFLD. The inflammatory process, cellular alterations in hepatocytes and stellate cells, hypercaloric diet, and sedentarism aggravate the prognosis of patients with MAFLD. Thus, to understand the modulation of the physiopathology of MAFLD, it is necessary to include the organokines involved in this process (adipokines, myokines, osteokines, and hepatokines) and their clinical relevance to project future perspectives of this condition and bring to light new possibilities in therapeutic approaches. Adipokines are responsible for the activation of distinct cellular signaling in different tissues, such as insulin and pro-inflammatory cytokines, which is important for balancing substances to avoid MAFLD and its progression. Myokines improve the quantity and quality of adipose tissues, contributing to avoiding the development of MAFLD. Finally, hepatokines are decisive in improving or not improving the progression of this disease through the regulation of pro-inflammatory and anti-inflammatory organokines.

show abstract

“…В настоящий момент МАЖБП занимает твердые позиции в списке наиболее распространенных заболеваний печени [1,3,17,23,24]. Согласно последнему систематическому обзору распространенность МАЖБП в большинстве регионов мира значительно превышает 20% и имеет тенденцию к росту [25].…”

Section: эпидемиологическая структура факторы риска и ассоциированные...unclassified

Metabolically associated fatty liver disease – a disease of the 21st century: A review

Маев

Andreev

Kucheryavy³

2022

Consilium Medicum

View full text Add to dashboard Cite

Metabolically associated fatty liver disease (MAFLD) is a widespread chronic disease characterized by increased accumulation of fat in the liver, which is based on metabolic dysfunction. The incidence of MAFLD is well over 20% in most regions of the world and is on an increasing trend. Current thinking considers the etiology and pathogenesis of MAFLD under the concept of "multiple parallel blows". According to this model, the development and progression of the disease are due to the interaction of multiple genetic, environmental and adaptive factors, which include specific genetic polymorphisms (e.g., the PNPLA3 gene) and epigenetic modifications, dietary patterns (e.g. high saturated fat and fructose intake), sedentary activity, obesity, insulin resistance, dysregulation of adipokines, lipotoxicity, oxidative stress, and gut microbiota dysbiosis (small intestinal bacterial overgrowth syndrome). The basis for the diagnosis of MAFLD is the presence of proven hepatic steatosis in combination with one of the following criteria: overweight/obesity, presence of type 2 diabetes mellitus, signs of metabolic dysregulation. Nonmedicamental therapies recommended for patients with MAFLD include weight loss (if overweight or obese), reduction of saturated fatty acid and fructose intake, and inclusion of adequate amounts of omega-3 polyunsaturated fatty acids and dietary fibre (psyllium) in the diet. Pharmacotherapy of MAFLD should be aimed at correcting insulin resistance, improving liver function and reducing the risk of associated diseases.

show abstract

Metabolic associated fatty liver disease and acute-on-chronic liver failure: common themes for common problems

Cited by 7 publications

References 105 publications

A Case of Recent Liver Injury Induced by Benzbromarone

A Case of Recent Liver Injury Induced by Benzbromarone

Underlying Mechanisms behind the Brain–Gut–Liver Axis and Metabolic-Associated Fatty Liver Disease (MAFLD): An Update

Metabolically associated fatty liver disease – a disease of the 21st century: A review

Contact Info

Product

Resources

About